C4 Therapeutics, Inc. (CCCC) Stock Forecast
CCCC analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.75 / 5 from 8 analysts
- Price target
- $12.86 average of analyst targets
- Upside to target
- +365.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.20
- 52-week range
- $1.71 – $4.67
CCCC analyst ratings
8 analystsNumber of analysts at each rating.
CCCC price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CCCC earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.21 | −$0.25 | −$0.17 | −$0.30 | +28.2% | 5 |
| Current fiscal year (2026) | −$0.86 | −$0.96 | −$0.74 | −$1.14 | +24.7% | 5 |
| Next fiscal year (2027) | −$0.96 | −$1.11 | −$0.82 | −$0.86 | −12.4% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CCCC revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $8.8M | $0 | $25.0M | −21.2% | 6 |
| Current fiscal year (2026) | $26.4M | $13.0M | $43.0M | −26.6% | 6 |
| Next fiscal year (2027) | $22.3M | $13.0M | $31.0M | −15.6% | 6 |
CCCC EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CCCC revenue: reported and forecast
CCCC EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.25 | −$0.25 | −$0.22 | −$0.22 | −$0.21 | −16.0% | 3 up · 0 down |
| Current fiscal year (2026) | −$0.96 | −$0.96 | −$0.89 | −$0.89 | −$0.86 | −10.5% | 3 up · 0 down |
| Next fiscal year (2027) | −$1.04 | −$1.04 | −$1.00 | −$1.00 | −$0.96 | −7.5% | 2 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CCCC earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CCCC beat in 7 of 12.
What analysts expect from CCCC
8 analysts cover C4 Therapeutics; their consensus rating is strong buy (4.75 on a 1–5 scale, where 5 is a strong buy). The average price target is $12.86, 365.0% above the latest close of $2.77. Analysts expect earnings of −$0.86 per share for 2026, +24.7% from a year earlier. For 2027 the average estimate is −$0.96 per share on revenue of $22.3 million. C4 Therapeutics beat the EPS estimate in 7 of the last 12 quarters.
Related: CCCC income statement, CCCC key metrics, CCCC chart. See the CCCC stock overview for the latest quote and news.
CCCC forecast FAQ
What is C4 Therapeutics's price target?
The average analyst price target for C4 Therapeutics is $12.86, 365.0% above the latest close of $2.77.
Is C4 Therapeutics a buy, hold or sell?
Of 8 analysts covering C4 Therapeutics, 6 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is C4 Therapeutics's EPS forecast?
Analysts forecast −$0.86 per share for 2026 (range −$0.96 to −$0.74); for 2027 the estimate is −$0.96.
What is C4 Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $26.4 million, growth of −26.6%; for 2027 it is $22.3 million.
When does C4 Therapeutics report earnings?
C4 Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.20.
Does C4 Therapeutics usually beat earnings estimates?
C4 Therapeutics reported EPS at or above the analyst estimate in 7 of the last 12 quarters.